Voya Investment Management LLC Trims Holdings in Syndax Pharmaceuticals, Inc. $SNDX

Voya Investment Management LLC trimmed its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 5.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 46,189 shares of the company’s stock after selling 2,642 shares during the quarter. Voya Investment Management LLC owned about 0.05% of Syndax Pharmaceuticals worth $567,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SNDX. Voloridge Investment Management LLC bought a new position in shares of Syndax Pharmaceuticals in the 4th quarter worth approximately $1,045,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Syndax Pharmaceuticals by 23.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 170,100 shares of the company’s stock worth $2,249,000 after purchasing an additional 32,653 shares during the period. Rhumbline Advisers lifted its stake in shares of Syndax Pharmaceuticals by 6.5% in the 1st quarter. Rhumbline Advisers now owns 120,810 shares of the company’s stock worth $1,484,000 after purchasing an additional 7,361 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in shares of Syndax Pharmaceuticals in the 1st quarter worth approximately $162,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Syndax Pharmaceuticals by 2.5% in the 1st quarter. Bank of New York Mellon Corp now owns 229,758 shares of the company’s stock worth $2,823,000 after purchasing an additional 5,497 shares during the period.

Insider Activity

In related news, CEO Michael A. Metzger sold 157,307 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $16.41, for a total value of $2,581,407.87. Following the completion of the transaction, the chief executive officer owned 298,661 shares of the company’s stock, valued at approximately $4,901,027.01. This represents a 34.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Dennis Podlesak sold 19,200 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.84, for a total value of $304,128.00. Following the completion of the sale, the director owned 191,763 shares in the company, valued at approximately $3,037,525.92. This represents a 9.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 204,537 shares of company stock valued at $3,265,935 in the last ninety days. Company insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on SNDX shares. BTIG Research reissued a “buy” rating and issued a $56.00 target price on shares of Syndax Pharmaceuticals in a report on Friday, September 19th. Stifel Nicolaus started coverage on shares of Syndax Pharmaceuticals in a report on Wednesday, September 10th. They issued a “buy” rating and a $44.00 target price for the company. The Goldman Sachs Group increased their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, September 5th. Citigroup increased their price objective on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Finally, UBS Group cut their price objective on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $39.22.

Syndax Pharmaceuticals Stock Up 4.3%

Shares of NASDAQ:SNDX opened at $15.68 on Friday. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $22.50. The business has a fifty day moving average of $14.05 and a two-hundred day moving average of $12.09. The stock has a market cap of $1.35 billion, a P/E ratio of -4.03 and a beta of 0.72. The company has a quick ratio of 4.55, a current ratio of 4.71 and a debt-to-equity ratio of 2.06.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.18. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The business had revenue of $37.96 million for the quarter, compared to the consensus estimate of $26.64 million. During the same quarter in the prior year, the business posted ($0.80) EPS. The business’s revenue for the quarter was up 984.5% on a year-over-year basis. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).